<sec id="sec2.1">
        <title><DRUG_CLASS>BRAF Inhibitors</DRUG_CLASS> Activate <PROTEIN_FAMILY>MEK</PROTEIN_FAMILY> and <PROTEIN_FAMILY>ERK</PROTEIN_FAMILY> in <CELL_LINE>RAS Mutant Melanoma Cells</CELL_LINE></title>
        <p>We selected four drugs for our studies (<xref ref-type="fig" rid="fig8">Figures S1</xref>A–S1D). <DRUG>Sorafenib</DRUG> is a <DRUG_CLASS>class II (inactive conformation binder)</DRUG_CLASS> drug (<xref ref-type="bibr" rid="bib28">Wan et al., 2004</xref>) that inhibits <GENE_PROTEIN><sup>V600E</sup>BRAF</GENE_PROTEIN> at 40 nM, CRAF at 13 nM, and several other kinases in the low nM range (<xref ref-type="bibr" rid="bib30">Wilhelm et al., 2004</xref>). <DRUG normalization="Sorafenib">It</DRUG> is the least-selective drug that we used. <DRUG>PLX4720</DRUG> is a <DRUG_CLASS>class I (active conformation binder) inhibitor</DRUG_CLASS> that is highly selective and inhibits <GENE_PROTEIN><sup>V600E</sup>BRAF</GENE_PROTEIN> at 13 nM (<xref ref-type="bibr" rid="bib27">Tsai et al., 2008</xref>). <DRUG>885-A</DRUG> (<xref ref-type="fig" rid="fig8">Figure S1</xref>C) is a close analog of the <DRUG_CLASS>class I inhibitor</DRUG_CLASS> <DRUG>SB590885</DRUG> (<xref ref-type="bibr" rid="bib16">King et al., 2006</xref>) that is also highly selective for <GENE_PROTEIN>BRAF</GENE_PROTEIN>. <DRUG normalization="885-A">It</DRUG> inhibits <GENE_PROTEIN><sup>V600E</sup>BRAF</GENE_PROTEIN> at 2 nM (<xref ref-type="fig" rid="fig8">Figure S1</xref>E), is ineffective against a panel of 64 other protein kinases (<xref ref-type="sec" rid="app1">Table S1</xref>), and preferentially blocks <CELL_LINE><GENE_PROTEIN>BRAF</GENE_PROTEIN> mutant cancer cell</CELL_LINE> proliferation (<xref ref-type="fig" rid="fig8">Figure S1</xref>F). Finally, we also used the potent and selective <DRUG_CLASS><PROTEIN_FAMILY>MEK</PROTEIN_FAMILY> inhibitor</DRUG_CLASS> <DRUG>PD184352</DRUG> (<xref ref-type="bibr" rid="bib26">Sebolt-Leopold et al., 1999</xref>).</p>
        <p>As expected, <DRUG normalization="Sorafenib, PLX4720, 885-A, PD184352 ">all four drugs</DRUG> blocked <PROTEIN_FAMILY>ERK</PROTEIN_FAMILY> activity in <CELL_LINE><GENE_PROTEIN>BRAF</GENE_PROTEIN> mutant A375 melanoma cells</CELL_LINE> (<xref ref-type="fig" rid="fig1">Figure 1</xref>A; see <xref ref-type="sec" rid="app1">Table S2</xref>). Similarly, <DRUG normalization="Sorafenib, PLX4720, 885-A, PD184352 ">all four drugs</DRUG> inhibited <PROTEIN_FAMILY>ERK</PROTEIN_FAMILY> in <CELL_LINE>SkMel24</CELL_LINE>, <CELL_LINE>SkMel28</CELL_LINE>, <CELL_LINE>D25</CELL_LINE>, and <CELL_LINE>WM266.4 cells</CELL_LINE>, <CELL_LINE normalization="SkMel24, SkMel28, D25, WM226.4">another four lines</CELL_LINE> that express mutant <GENE_PROTEIN>BRAF</GENE_PROTEIN> (<xref ref-type="fig" rid="fig8">Figure S1</xref>G). We also tested <DRUG normalization="Sorafenib, PLX4720, 885-A, PD184352">the drugs</DRUG> in <CELL_LINE normalization="D04 NRAS mutant cells"><CELL_LINE>D04</CELL_LINE>, <CELL_LINE normalization="MM415 NRAS mutant cells"><CELL_LINE>MM415</CELL_LINE>, <CELL_LINE normalization="MM485 NRAS mutant cells"><CELL_LINE>MM485</CELL_LINE>, and <CELL_LINE normalization="WM852 NRAS mutant cells"><CELL_LINE>WM852</CELL_LINE> NRAS mutant cells</CELL_LINE></CELL_LINE></CELL_LINE></CELL_LINE> (<xref ref-type="sec" rid="app1">Table S2</xref>). As expected, <DRUG>PD184352</DRUG> and <DRUG>sorafenib</DRUG> inhibited <PROTEIN_FAMILY>ERK</PROTEIN_FAMILY> in <CELL_LINE normalization="D04, MM415, MM485, WM852 NRAS mutant cells">all of these lines</CELL_LINE> (<xref ref-type="fig" rid="fig1">Figure 1</xref>A). Surprisingly, however, <DRUG>PLX4720</DRUG> and <DRUG>885-A</DRUG> caused an unexpected increase in <PROTEIN_FAMILY>ERK</PROTEIN_FAMILY> activity in the <CELL_LINE normalization="D04, MM415, MM485, WM852 NRAS mutant cells">NRAS mutant cells</CELL_LINE> (<xref ref-type="fig" rid="fig1">Figure 1</xref>A). <GENE_PROTEIN>NRAS</GENE_PROTEIN> or <GENE_PROTEIN>CRAF</GENE_PROTEIN> depletion by RNA interference (RNAi) blocked <PATHWAY><PROTEIN_FAMILY>MEK</PROTEIN_FAMILY>/<PROTEIN_FAMILY>ERK</PROTEIN_FAMILY></PATHWAY> activation by <DRUG>PLX4720</DRUG> and <DRUG>885-A</DRUG> in <CELL_LINE>NRAS mutant cells</CELL_LINE> (<xref ref-type="fig" rid="fig1">Figure 1</xref>B and 1C) and we show that <DRUG>885-A</DRUG> activated <GENE_PROTEIN>CRAF</GENE_PROTEIN> in <CELL_LINE normalization="D04, MM415, MM485, WM852 NRAS mutant cells">these cells</CELL_LINE> (<xref ref-type="fig" rid="fig1">Figure 1</xref>D). We previously reported that oncogenic <PROTEIN_FAMILY>RAS</PROTEIN_FAMILY> requires <GENE_PROTEIN>CRAF</GENE_PROTEIN> but not <GENE_PROTEIN>BRAF</GENE_PROTEIN> to activate <PROTEIN_FAMILY>MEK</PROTEIN_FAMILY> (<xref ref-type="bibr" rid="bib4">Dumaz et al., 2006</xref>) and consistent with this, <GENE_PROTEIN>BRAF</GENE_PROTEIN> is inactive in <CELL_LINE>NRAS mutant cells</CELL_LINE> (<xref ref-type="fig" rid="fig1">Figure 1</xref>E). These data therefore present an intriguing paradox. <GENE_PROTEIN>BRAF</GENE_PROTEIN> is not active and is not required for <PATHWAY><PROTEIN_FAMILY>MEK</PROTEIN_FAMILY><PROTEIN_FAMILY>/ERK</PROTEIN_FAMILY></PATHWAY> activation in <CELL_LINE>RAS mutant cells</CELL_LINE>. Nevertheless, <GENE_PROTEIN>BRAF</GENE_PROTEIN> inhibitors hyperactivate <GENE_PROTEIN>CRAF</GENE_PROTEIN> and <PROTEIN_FAMILY>MEK</PROTEIN_FAMILY> in <CELL_LINE normalization="RAS mutant cells">these cells</CELL_LINE>, so we studied the underlying mechanism(s).</p>
      </sec>